HoldsUp

Huberman Lab · 2026-03-09 · Andrew Huberman (host), Alex Marson

Avoiding, Treating & Curing Cancer | Dr. Alex Marson

59 research-tied claims examined: 1 contradicted 1 overstated 1 context 52 supported 4 unverified

1 Contradicted by research
1:49:50Andrew Huberman (host)contradictedhigh

Saporin toxin was put on the tip of an umbrella and used to assassinate someone on a bridge in an act of international espionage.

"In our case, we used saporin toxin, which I think is most infamous because it was put on the tip of an umbrella and used to assassinate somebody on a bridge someplace in some sort of international spy warfare in the last 20 years or so." (said at 1:49:50)

The speaker confuses saporin with ricin. The famous 'umbrella assassination' occurred on September 7, 1978, on Waterloo Bridge in London, where Bulgarian dissident Georgi Markov was assassinated using a pellet suspected of containing ricin (a ribosome-inactivating protein derived from Ricinus communis), not saporin (a ribosome-inactivating protein derived from Saponaria officinalis / soapwort). Furthermore, the incident occurred in 1978 (over 40 years ago), not in the last 20 years.

1 Overstated
0:44:09Andrew Huberman (host)overstatedmoderate

Airline pilots have higher rates of cancer, in part due to elevated atmospheric cosmic radiation exposure.

"And we know pilots—and this is for other reasons, cuz atmospherically they're exposed to more radiation—cancer rates are higher in pilots." (said at 0:44:09)

The claim is overstated. Large multicenter cohort studies show that overall cancer mortality and incidence among airline pilots are actually lower than in the general population (standardized mortality ratio for all cancers ~0.64–0.68), largely due to a strong 'healthy worker effect' and lower smoking rates. However, pilots do have significantly elevated rates of specific malignancies—primarily cutaneous malignant melanoma and keratinocyte (non-melanoma) skin cancers (approximately double the general population rate). Furthermore, extensive cohort studies examining cumulative occupational cosmic radiation doses have found no consistent dose-response relationship with cancer incidence or mortality, suggesting other factors (such as UV radiation exposure during leisure time/layovers or circadian disruption) may explain the excess skin cancer risk.

1 Needs context
2:02:45Alex Marsonneeds contexthigh

If a genetic edit is performed on an embryo, every developing cell in that embryo will carry the edit, including the germline cells (sperm and egg).

"If you do it in an embryo, all of a sudden every cell in the developing embryo will have it, including sperm and egg." (said at 2:02:45)

The speaker's statement describes the fundamental distinction between somatic cell editing and germline (embryo) editing: editing at the one-cell zygote stage aims to introduce the genetic modification into all descendant somatic and germline lineages (sperm and egg), thereby making it heritable. However, in practice, editing an embryo does not guarantee that every single developing cell carries the edit due to the major biological and technical hurdle of genetic mosaicism (where Cas9 cleavage or repair occurs after cleavage divisions begin, leading to a mixture of edited and unedited cells or different edit types across blastomeres). Thus, while the theoretical/conceptual principle of germline editing is correctly stated, the categorical claim that 'every cell' will have it requires qualification.

52 Supported by research
0:00:00Alex Marsonsupportedhigh

CAR-T cell therapy involves genetically engineering T cells with a synthetic chimeric antigen receptor designed in the lab to target and destroy cancer cells upon reinfusion into a patient.

"We're living in this amazing moment of biology where we can put a gene that encodes something on the surface of T cells that will make them programmed to search and destroy for cancer cells. Now, this is largely known as CAR-T cells, chimeric antigen receptor. This is a receptor that it was designed in a lab, does not exist in nature. When those T cells get reinfused into a patient the way that you get like a a blood transfusion, those CARs are directed to go against cancers." (said at 0:00:00)

The speaker's description of chimeric antigen receptor (CAR) T-cell therapy accurately describes the established biological and therapeutic mechanism of CAR-T therapy. T cells are genetically engineered to express synthetic receptors (CARs) designed to target specific tumor antigens and are reinfused into patients as adoptive cellular immunotherapy.

0:07:00Alex Marsonsupportedhigh

The innate immune system includes dendritic cells and macrophages that detect broad patterns of foreign or damaged material and trigger alarm signals that recruit the adaptive immune system.

"And with the innate immune system, which consists of cells like dendritic cells, macrophages, these are cells that are going around and they're looking for patterns of things that just generally aren't in human cells. Some signs of damage, some signs of things that are just that shouldn't be there in a in a generic way in a healthy human. When those first alarm systems get triggered, all of a sudden these innate immune systems start releasing things. They change their state and they send off an alarm to other cells in the immune system. And then they often recruit in the second arm of the immune system that you mentioned, the adaptive immune system." (said at 0:07:00)

The speaker's statement accurately summarizes foundational immunology: the innate immune system relies on sentinel cells such as macrophages and dendritic cells equipped with pattern recognition receptors (PRRs) to detect broad pathogen-associated molecular patterns (PAMPs, foreign structures) and damage-associated molecular patterns (DAMPs, signs of cellular injury). Activation of these pathways triggers cytokine and chemokine secretion and antigen presentation, which bridge innate signaling to the recruitment and activation of the adaptive immune response.

  • supports: Toll-Like Receptors in Adaptive Immunity. (Handbook of experimental pharmacology 2022) · cited 44x in the literature
    "The pattern recognition receptors (PRRs) play a crucial role in recognizing different PAMPs or MAMPs and DAMPs to initiate the pro-inflammatory immune response to clear them. Toll-like receptors (TLRs) are first recognized PRRs and their discovery proved milestone in the field of immunology as it filled the gap between the first recognition of the pathogen by the immune system and the initiation of the appropriate immune response required to clear the infection by innate immune cells (macrophages, neutrophils, dendritic cells or DCs, and mast cells)." (abstract, results, passage verified)
    pubmedfull study (doi)
  • supports: Severe Acute Respiratory Syndrome Coronavirus 2: The Role of the Main Components of the In… (Inflammation 2021) · cited 18x in the literature
    "The innate immune response is carried out by sentinel cells such as monocytes/macrophages and dendritic cells and by receptors known as pattern recognition receptors (PRR). These receptors can recognize various components of the virus, which lead to intracellular signaling and subsequently the synthesis of various cytokines. These cytokines then recruit other immune cells, activate adaptive immune responses, and inhibit viral spreading." (abstract, results, passage verified)
    pubmedfull study (doi)
0:08:10Alex Marsonsupportedhigh

Each T cell generates a unique receptor through random somatic DNA recombination rather than inheriting the specific sequence intact through the germline.

"One of the amazing things about the T cells is that each T cell naturally in our body it's one of the few places where each cell will actually have a different piece of DNA that's not inherited in in our germline sequence. Each T cell will make its own receptor that is generated largely at random to go and sense something" (said at 0:08:10)

The speaker's claim is completely accurate and reflects foundational immunology. T cells (and B cells) generate unique antigen receptor genes through somatic V(D)J recombination, a process where germline gene segments are quasi-randomly rearranged and joined in developing lymphocytes to produce a highly diverse repertoire of T cell receptors, rather than inheriting fully assembled receptor sequences directly through the germline.

0:11:13Alex Marsonsupportedhigh

Developing T cells undergo positive and negative selection in the thymus, where cells that bind self-antigens are eliminated to prevent autoimmunity.

"So they they've have are making these sensors at largely at random. And then in the they get culled, they get selected, and they the ones that by accident are generated that recognize something that is supposed to be in your body, if if the if the T cell engages a natural target in the thymus, those cells will die. And so what emerges from the thymus should be, and this is not perfect process, but should be things that have are have emerged at random, but then are selected to remove things that recognize your own body targets." (said at 0:11:13)

The speaker accurately describes the fundamental mechanism of central immunological tolerance and negative selection in the thymus. Developing T cells randomly generate diverse T-cell receptors through somatic recombination; during thymic selection (central tolerance), thymocytes that bind self-antigen/MHC complexes with high affinity undergo apoptosis (negative selection) to prevent autoreactive T cells from entering the periphery and causing autoimmunity. This is a well-established textbook immunological principle confirmed by extensive experimental and clinical evidence.

0:12:51Alex Marsonsupportedhigh

B cells generate unique antibodies through random somatic recombination and selection processes before releasing antibodies into the bloodstream.

"B cells are this other type of lymphocyte that work in coordination with T cells, and they're the antibody producing cells. So they actually have a similar process where they're generating different antibodies at random with through a similar kind of recombination event. They have their own form of selection that they go through. And then those antibodies can then be released into the bloodstream and and are the basis for protection against infections after we get them." (said at 0:12:51)

The speaker's statement accurately summarizes fundamental principles of adaptive immunology. B cells generate a diverse repertoire of unique antigen receptors (membrane-bound antibodies) through random somatic V(D)J gene recombination, undergo central and peripheral selection processes to establish tolerance and receptor functionality, and upon activation and differentiation into plasma cells, secrete soluble antibodies into the bloodstream to protect against pathogens.

0:17:15Alex Marsonsupportedvery low

In mouse experiments, obesity induced by a high-fat diet qualitatively altered the inflammatory skin response to an allergen and caused standard allergy-blocking antibody treatments to fail or worsen inflammation.

"He did experiments in my lab where he exposed something allergen, something that irritated the skin, and caused an allergic type reaction in the skin of mice. He did it in mice that were eating a normal mouse diet versus a high fat diet that caused obesity. And what we saw was that it was actually not just a quality quantitative difference in the immune system, but actually qualitative difference. The actual type of inflammation, the cell responses were different in in the mice eating a high fat diet. And I think we haven't done enough studies like that where we actually start playing with the variables of life and test them in mechanistic way to isolate individual variants. What was interesting there was that the allergic reaction actually looked totally different in the obese mice. And if we used surrogates that are for the types of drugs that are being used now to treat severe allergy. So, we gave antibodies that block allergic responses. The normal flip diet mice would respond favorably to these. It It they didn't help the the mice that had the obese high fat diet response to inflammation. And in some cases it actually maybe made it worse." (said at 0:17:15)

The speaker accurately describes findings from a 2022 Nature study by Bapat et al. (PMID 35355021). The researchers demonstrated in mouse models of atopic dermatitis that obesity qualitatively altered the immune response from a Th2-predominant phenotype to a more severe Th17-driven inflammation, causing biologic therapies targeting Th2 cytokines (standard allergic inflammation blockers) to fail and exacerbate disease in obese mice. Because this evidence is derived from animal/preclinical models, the GRADE certainty is very low.

  • supports: Obesity alters pathology and treatment response in inflammatory disease. (Nature 2022) · cited 246x in the literature
    "Here, using two models of atopic dermatitis, we show that lean and obese mice mount markedly different immune responses. Obesity converted the classical type 2 T helper (T H 2)-predominant disease associated with atopic dermatitis to a more severe disease with prominent T H 17 inflammation. We also observed divergent responses to biologic therapies targeting T H 2 cytokines, which robustly protected lean mice but exacerbated disease in obese mice." (abstract, passage verified)
    pubmedfull study (doi)
0:19:44Alex Marsonsupportedhigh

Specific genetic mutations can impair distinct branches of the innate or adaptive immune system, making individuals abnormally vulnerable to specific types or severities of infection.

"There's been a lot of work on genetic determinants and and there's extreme cases where people have a genetic gap in their immune system where they're really susceptible to something that healthy people should not be susceptible to. And you see that there's certain types of infections that either happen or happen with a different type of severity in people with genetic deficits in certain certain branches of their immune system. And And in some cases you can pinpoint that we just talked about the innate immune response, the adaptive immune response. You can see that certain genetic mutations that people inherit could influence one or multiple branches of that immune responses and the consequences that you that manifests itself with different types of infection." (said at 0:19:44)

The speaker's statement accurately reflects established principles in human immunology and medical genetics. Monogenic inborn errors of immunity (IEIs, historically called primary immunodeficiencies) comprise over 480 identified single-gene disorders. Mutations affecting distinct innate immune pathways (e.g., TLR/IL-1R signaling, type I interferon pathways, complement, or phagocyte function) or adaptive immune pathways (e.g., B-cell, T-cell, or combined deficiencies) predispose individuals to specific categories of pathogens (viral, bacterial, fungal, or mycobacterial) or unusually severe clinical courses compared to immunologically healthy individuals.

0:22:14Alex Marsonsupportedhigh

Controlled early childhood exposure to peanuts helps maintain immunological tolerance and protects against the development of peanut allergies.

"And I think peanut allergies there there is strong evidence that exposure to peanuts can be beneficial in people who are not yet allergic." (said at 0:22:14)

The speaker's assertion is fully supported by high-quality randomized controlled trial evidence. Landmark trials including the LEAP (Learning Early About Peanut Allergy) and EAT studies, as well as their long-term follow-ups into adolescence, demonstrated that introducing peanut products into the diets of non-allergic infants (including high-risk infants) significantly reduces the subsequent incidence of peanut allergy by 75% or more and induces durable immunological tolerance.

0:23:37Alex Marsonsupportedhigh

Autoimmune diseases result when self-reactive T cells escape thymic negative selection and secondary peripheral tolerance mechanisms fail, leading to immune attack on specific host tissues like joint targets in rheumatoid arthritis, pancreatic insulin-producing cells in type 1 diabetes, or myelin in multiple sclerosis.

"In practice, T cells escape from the thymus that do recognize our own self antigens. And there's actually secondary mechanisms that to block that, but autoimmune diseases emerge when those normal checks fail... If if you if your immune system starts recognizing targets in your joints, it can cause rheumatoid arthritis. If it's in those cells that produce insulin in the pancreas, it causes type 1 or childhood diabetes. Um if it's the myelin myelinated cells in the brain, it's multiple sclerosis." (said at 0:23:37)

The speaker provides an accurate, textbook description of autoimmune disease pathogenesis. Autoreactive T cells that escape thymic negative selection (central tolerance) are normally restrained in the periphery by regulatory T cells, anergy, and other peripheral tolerance mechanisms. When these checkpoints fail, self-reactive immune responses drive tissue-specific pathology, including synovial joint inflammation in rheumatoid arthritis, destruction of insulin-producing pancreatic beta cells in type 1 diabetes, and demyelination of the central nervous system in multiple sclerosis.

0:26:40Alex Marsonsupportedhigh

Immune cells secrete cytokines into the bloodstream that act as distributed chemical signals capable of inducing systemic responses like fever.

"Major ones are—they're called cytokines, and they can act locally, but they can also have more distributed effects. And some of the things that the cytokines can do can influence what can cause the development of fever. All right, so you can have these sort of cascading effects of something being recognized at a particular site of the body, then sending distributed signals to the blood that will make us feel sick." (said at 0:26:40)

The speaker's statement accurately describes standard immunological physiology. Immune cells recognize local pathogens or damage and secrete pyrogenic and proinflammatory cytokines (such as IL-1β, IL-6, and TNF-α) that act both locally and systemically via circulation to signal the brain/hypothalamus, driving systemic responses such as fever and sickness behavior.

0:11:00Alex Marsonsupportedhigh

The human thymus gland gradually shrinks in size as a person ages.

"the thymus is an organ that it does sort of shrink as we age but at least in childhood it's it sort of lies by your heart and it is the place where T cells go and a key place of their education." (said at 0:11:00)

The speaker's statement accurately reflects well-established human immunology and anatomy. The thymus is located in the anterior mediastinum (adjacent to the heart) and serves as the primary site of T-cell maturation, selection, and 'education'. As individuals age—starting after puberty—the thymus undergoes progressive structural atrophy and fatty replacement (known as age-related thymic involution), leading to reduced naive T-cell output.

0:36:00Alex Marsonsupportedhigh

Smoking causes chemicals to enter the lungs that induce DNA damage and increase the accumulation of genetic mutations.

"When smoking causes chemicals to go into your lungs, the lung cells get exposed to these chemicals that then cause higher amounts of DNA damage, more mutations." (said at 0:36:00)

The speaker accurately states that tobacco smoke exposes lung cells to carcinogens that induce DNA damage and lead to an increased burden of somatic mutations. Whole-genome sequencing of human bronchial epithelial cells directly confirms that cigarette smoke carcinogens cause DNA damage and significantly increase the mutational burden (adding 1,000 to 10,000 somatic mutations per cell) as well as driver mutations in lung tissue.

  • supports: DNA Damage, Mutagenesis and Cancer. (International journal of molecular sciences 2018) · cited 524x in the literature
    "Generation of DNA damage (also known as DNA adducts or lesions) induced by these agents is an important first step in the process of carcinogenesis... Damaged DNA replication may lead to gene mutations, which in turn may give rise to altered proteins... This is exemplified in the long-term use of tobacco being responsible for an increased risk of lung cancer." (abstract, background)
    pubmedfull study (doi)
  • supports: Tobacco smoking and somatic mutations in human bronchial epithelium. (Nature 2020) · cited 568x in the literature
    "Tobacco smoking causes lung cancer 1-3 , a process that is driven by more than 60 carcinogens in cigarette smoke that directly damage and mutate DNA 4,5 . The profound effects of tobacco on the genome of lung cancer cells are well-documented 6-10 , but equivalent data for normal bronchial cells are lacking. Here we sequenced whole genomes of 632 colonies derived from single bronchial epithelial cells across 16 subjects. Tobacco smoking was the major influence on mutational burden, typically adding from 1,000 to 10,000 mutations per cell" (abstract, results, passage verified)
    pubmedfull study (doi)
0:37:01Alex Marsonsupportedhigh

BRCA mutations predispose individuals to breast cancer and other forms of cancer.

"So, people will likely have heard of the BRCA or the BRCA genes, which predispose to breast cancer and other types of cancer." (said at 0:37:01)

Pathogenic variants in BRCA1 and BRCA2 are well-established cancer predisposition genes. Large prospective cohort studies and meta-analyses demonstrate that BRCA1/2 mutation carriers have substantially elevated lifetime risks of breast cancer (cumulative risk to age 80 of ~72% for BRCA1 and ~69% for BRCA2) and ovarian cancer (cumulative risk ~44% for BRCA1 and ~17% for BRCA2), as well as increased risks for other malignancies including pancreatic, prostate, and gastric cancers.

0:37:46Alex Marsonsupportedhigh

Ultraviolet (UV) radiation causes DNA damage in the skin and is a risk factor for melanoma.

"sun exposure for melanoma... But clearly UV is a risk factor for DNA damage in the skin." (said at 0:37:46)

Ultraviolet (UV) radiation is well established as a direct cause of DNA damage (such as cyclobutane pyrimidine dimers and oxidative DNA lesions) in skin cells, and extensive epidemiological and mechanistic evidence identifies UV radiation and sun exposure as major risk factors for cutaneous melanoma.

0:38:55Alex Marsonsupportedhigh

BRCA mutations account for only a small minority of overall cancers, but confer a very high individual lifetime cancer risk to carriers.

"In the scheme of cancers that develop, it's a minority. It's a relatively small number of the full set of cancers. The problem is if you inherit a BRCA mutation as an individual, you have a very high risk of developing cancer." (said at 0:38:55)

The speaker accurately states that BRCA1 and BRCA2 pathogenic variants account for only a small minority of overall cancers (hereditary breast and ovarian cancer syndromes account for ~5-10% of breast cancers and an even smaller percentage of all cancers combined), yet confer an exceptionally high lifetime cancer risk to individual carriers. Large prospective cohort data demonstrate that female carriers face cumulative lifetime breast cancer risks of approximately 69% to 72% and ovarian cancer risks up to 44% by age 80, along with elevated risks for other malignancies (such as prostate and pancreatic cancers).

0:39:40Alex Marsonsupportedhigh

Studying male breast cancer cases aided in the identification of BRCA genes due to the rarity of breast cancer in men.

"It actually was men were some of the ways that those BRCA genes were identified, because it's so rare for men to develop breast cancer. The ones who did develop it, there was a thought, "Well, maybe there's an underlying genetic predisposition," and that helped identify those genes." (said at 0:39:40)

Male breast cancer is exceptionally rare, accounting for less than 1% of all breast cancer cases. In the early 1990s, after BRCA1 on chromosome 17q was discovered to account for many hereditary female breast/ovarian cancer families but few male breast cancer cases, researchers specifically analyzed families with male breast cancer to identify and map the second major breast cancer susceptibility gene, BRCA2, to chromosome 13q12-13.

0:45:59Alex Marsonsupportedmoderate

Meat consumption has been implicated as a potential carcinogen, particularly for colorectal cancer.

"yes, meat in general has been implicated as a potential carcinogen, especially in colorectal cancer. There's some data around that." (said at 0:45:59)

The speaker accurately notes that meat consumption has been implicated as a potential carcinogen, particularly with respect to colorectal cancer. In 2015, the International Agency for Research on Cancer (IARC/WHO) classified processed meat as 'carcinogenic to humans' (Group 1) and red meat as 'probably carcinogenic to humans' (Group 2A), largely based on epidemiological and mechanistic evidence linking intake to colorectal cancer. Comprehensive systematic reviews and meta-analyses of prospective cohort studies consistently show statistically significant positive associations between red and processed meat intake and colorectal cancer incidence.

0:53:14Alex Marsonsupportedhigh

Immune checkpoint inhibitor therapies targeting PD-1 and CTLA-4 block natural inhibitory receptors on T cells to enhance anti-tumor immune responses.

"The first place where this happened was in a class of medicines called checkpoint inhibitors. They are immunotherapy drugs. A lot of people will have heard of these things. PD-1, CTLA-4 are some targets where there are drugs that get infused that hit these things that are on the surface of T cells. And they actually are natural brakes to the T cells." (said at 0:53:14)

The speaker's statement accurately describes the established mechanism of immune checkpoint inhibitor therapies. Immune checkpoint inhibitors (such as antibodies targeting PD-1 and CTLA-4) target cell-surface inhibitory receptors ('natural brakes') on T lymphocytes. By blocking these inhibitory checkpoint pathways exploited by tumors to suppress immune surveillance, these therapies restore and enhance anti-tumor T-cell responses.

0:56:05Alex Marsonsupportedhigh

CAR-T cell therapy involves engineering a patient's T cells with an artificial chimeric antigen receptor using modified lentiviruses as gene delivery vectors.

"This has been done for certain types of leukemia and lymphoma, and there's been these amazing success stories... Her own T cells were genetically modified... Actually used viruses, lentiviruses. These are sort of modified HIV viruses to deliver this extra piece of DNA that encoded the CAR." (said at 0:56:05)

The speaker accurately describes the core mechanism and design of autologous chimeric antigen receptor (CAR) T-cell therapy. In CAR-T therapy for hematological malignancies such as leukemia and lymphoma (most notably CD19-targeted therapies like tisagenlecleucel), a patient's autologous T cells are harvested and genetically modified ex vivo using viral vectors, commonly HIV-1-derived lentiviral vectors (or retroviruses), to introduce recombinant DNA encoding the chimeric antigen receptor before being re-infused.

0:56:15Alex Marsonsupportedvery low

In 2012, Emily Whitehead became the first pediatric patient treated with CAR-T cell therapy for refractory leukemia at the University of Pennsylvania.

"The thing that woke up me and the world was in 2012, there was a young girl who was the first pediatric patient to be treated with a CAR-T cell for cancer. So, she's become a heroic figure, Emily Whitehead. She was I think eight at the time, and she had a form of leukemia that hadn't—it just was for some reason, whatever reason, it failed all the treatments... And so that was done in 2012. Emily Whitehead was eight. It was done as an experimental treatment at the University of Pennsylvania." (said at 0:56:15)

In April 2012, Emily Whitehead (then aged 6-7) became the first pediatric patient treated with CD19-directed CAR T-cell therapy (CTL019) for relapsed/refractory pre-B-cell acute lymphoblastic leukemia (ALL) at the Children's Hospital of Philadelphia/University of Pennsylvania. The clinical case was published by Grupp et al. in the New England Journal of Medicine in 2013. The patient experienced severe cytokine release syndrome successfully treated with tocilizumab and achieved complete remission. As a single case report / pilot series, the GRADE certainty for clinical outcomes from this design is very low.

  • supports: Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. (The New England journal of medicine 2013) · cited 3518x in the literature
    "Two children with relapsed and refractory pre-B-cell ALL received infusions of T cells transduced with anti-CD19 antibody and a T-cell signaling molecule (CTL019 chimeric antigen receptor T cells), at a dose of 1.4×10(6) to 1.2×10(7) CTL019 cells per kilogram of body weight... In one child, the cytokine-release syndrome was severe; cytokine blockade with etanercept and tocilizumab was effective in reversing the syndrome and did not prevent expansion of chimeric antigen receptor T cells or reduce antileukemic efficacy. Complete remission was observed in both patients and is ongoing in one patient at 11 months after treatment." (abstract, results, passage verified)
    pubmedfull study (doi)
0:59:54Alex Marsonsupportedhigh

In 2012, Emmanuelle Charpentier and Jennifer Doudna published a paper in Science describing the CRISPR technology for rewriting DNA sequences.

"2012 also was the year that a paper got published in Science by Emmanuelle Charpentier and Jennifer Doudna that introduced this new technology called CRISPR. And we can—we'll talk about this, but CRISPR fundamentally is a tool to rewrite DNA sequences. That came out in 2012." (said at 0:59:54)

In August 2012, a research team co-led by Emmanuelle Charpentier and Jennifer Doudna (with first author Martin Jinek) published a landmark paper in Science demonstrating that the Cas9 endonuclease can be programmed with synthetic single-guide RNAs to introduce site-specific double-stranded breaks in target DNA, establishing CRISPR-Cas9 as a versatile tool for genome editing.

0:57:11Alex Marsonsupportedhigh

Lentiviral vectors used to deliver genetic material in CAR-T cell therapies are engineered from modified human immunodeficiency virus (HIV).

"Actually used viruses, lentiviruses. These are sort of modified HIV viruses to deliver this extra piece of DNA that encoded the CAR." (said at 0:57:11)

Lentiviral vectors commonly used to deliver the chimeric antigen receptor (CAR) gene construct into T cells during CAR-T therapy manufacturing are engineered derivatives of the human immunodeficiency virus (HIV-1). Pathogenic viral genes are deleted or disabled, leaving modified viral sequences (such as LTRs and packaging signals) to safely deliver the genetic material into host cells. This shared genetic ancestry is well established and can even lead to documented false-positive results on HIV nucleic acid tests targeting residual lentiviral vector sequences.

0:59:17Alex Marsonsupportedvery low

Following CAR-T cell therapy in 2012, pediatric leukemia patient Emily Whitehead remained cancer-free and matriculated as a pre-med student at the University of Pennsylvania.

"And the story now is that now all these years later Emily Whitehead is not only cured of her leukemia, she's pre-med at the University of Pennsylvania." (said at 0:59:17)

Emily Whitehead was the first pediatric patient treated with CD19-directed CAR-T cell therapy (CTL019/tisagenlecleucel) for relapsed/refractory B-cell acute lymphoblastic leukemia at the Children's Hospital of Philadelphia / University of Pennsylvania in 2012. After life-threatening cytokine release syndrome successfully treated with tocilizumab, she achieved complete remission and has remained cancer-free for over a decade, subsequently matriculating at the University of Pennsylvania. Because this claim describes an individual case history, the certainty of evidence is graded as very low by design.

0:51:28Alex Marsonsupportedhigh

Cancer cells frequently evolve resistance to targeted molecular therapies through secondary genetic mutations, analogous to bacterial antibiotic resistance.

"cancer has ways of mutating around that and could develop resistance, the same way we talked about resistance in bacteria to antibiotics if they're exposed. Cancer cells can evolve quickly and can become resistant to these targeted modifications." (said at 0:51:28)

Extensive clinical and molecular oncology research demonstrates that cancer cells under selective pressure from targeted molecular therapies (such as tyrosine kinase inhibitors) frequently acquire resistance through secondary point mutations in the drug target, bypass signaling pathways, or other genetic alterations. This process of clonal evolution under therapeutic selection pressure is widely recognized as directly analogous to the Darwinian evolutionary selection observed in bacterial resistance to antibiotics.

1:01:20Alex Marsonsupportedhigh

CRISPR-engineered CAR T-cells are currently in clinical trials for solid tumors.

"We're now in clinical trials with these CRISPR engineered CAR T-cells and we're not just going after leukemias where these CAR T-cells have historically worked, but we're also thinking about can we make these work for the really common causes of cancer deaths: solid tumors." (said at 1:01:20)

Multiple Phase I/II clinical trials have evaluated or are currently evaluating CRISPR-edited CAR T-cell therapies in solid tumors, such as clear cell renal cell carcinoma (e.g., CTX130, an allogeneic CRISPR-Cas9 engineered CAR T-cell therapy) as well as gastrointestinal, lung, and other solid malignancies, alongside their established use in leukemias and lymphomas.

1:03:25Alex Marsonsupportedmoderate

Cancer incidence increases with age primarily because dividing cells accumulate mutations and DNA damage over time.

"most cancers, as you said, exactly as you said, there's this sort of increase and they're largely a disease of later stages of life. I think that the reason for that is, remember when we talked about what causes cancer, it's this evolution where certain cells start to accumulate mutations... And the more time you have cells dividing and sticking around in the body, they're accumulating more damage, and eventually you're more likely that that damage would actually transform the cells into a cancer cell." (said at 1:03:25)

Large-scale genomic and epidemiologic analyses demonstrate that cancer risk and incidence are strongly linked to the lifetime accumulation of somatic mutations arising during normal cell division and DNA replication. Landmark studies showed that the cumulative number of stem cell divisions across tissues explains approximately two-thirds of the variation in cancer risk and somatic mutation burden, leading to an age-dependent accumulation of cancer-associated mutations.

1:05:08Alex Marsonsupportedhigh

CD19 is expressed on the surface of normal healthy B cells as well as multiple types of B-cell leukemias and lymphomas.

"The leukemias themselves are a disease, a cancer of the immune cells, so they're cancer of B cells. And CD19 is found on the surface of a large number of different types of B cell leukemias and lymphomas... healthy B cells, actually also have CD19 on their surface." (said at 1:05:08)

CD19 is a hallmark lineage-specific surface marker expressed throughout normal B-cell development (from early pro-B/pre-B cells through mature B cells, down-regulated at the plasma cell stage) and is retained on the vast majority of B-cell leukemias and lymphomas (such as B-cell acute lymphoblastic leukemia, chronic lymphocytic leukemia, and non-Hodgkin B-cell lymphomas), making it a standard target for diagnostics and CAR T-cell therapies.

1:05:27Alex Marsonsupportedhigh

The human body can tolerate the collateral destruction of healthy B cells caused by CD19-targeted CAR T-cell therapy.

"What just turns out to be serendipitous is that the body can tolerate those cells going away. And so, what has made this a particularly effective and so safe and relatively well-tolerated treatment for cancer is that the collateral damage is actually not that damaging. That T cells in this case are not strictly distinguishing between cancer and health. They're not just getting the leukemia cells. They are getting collateral B cells. But, by and large, to a first approximation, people can live without those cells." (said at 1:05:27)

CD19-targeted CAR T-cell therapies do not distinguish between malignant and normal B cells, resulting in complete destruction of healthy CD19+ B cells (known as B-cell aplasia) as an expected 'on-target, off-tumor' effect. Clinical evidence demonstrates that this collateral loss is well-tolerated by patients: preexisting plasma cells often preserve baseline antibody levels, and any resulting hypogammaglobulinemia or infection risks are clinically manageable, often with intravenous immunoglobulin (IVIG) replacement and antimicrobial prophylaxis.

1:09:44Alex Marsonsupportedhigh

A draft of the human genome was completed around 2000 through an international multi-billion-dollar effort.

"And then around 2000, we get to the first draft of the human genome, which is this multi-billion dollar project across the world to come up with a draft of one human genome sequence. Milestone for biology and medicine." (said at 1:09:44)

The speaker's statement accurately describes the Human Genome Project (HGP). In June 2000, the completion of the initial working draft of the human genome was announced, and the corresponding papers by the International Human Genome Sequencing Consortium and Celera Genomics were published in February 2001. The HGP was a publicly funded, multi-billion-dollar international collaboration spanning multiple countries that produced the first comprehensive draft sequence of the human genome.

1:11:50Alex Marsonsupportedhigh

CRISPR repeat sequences naturally function as an adaptive immune defense mechanism in bacteria against bacteriophage viruses.

"And little by little by little it was worked out that these repeat sequences actually formed the basis of a kind of immune system for bacteria... bacteria are constantly being bombarded by certain types of viruses. They're called bacteriophage viruses. And bacteria have evolved a series of defense mechanisms to protect themselves from these viruses. CRISPR turns out to be a bacterial defense mechanism against viruses." (said at 1:11:50)

The speaker's statement accurately describes the natural biological function of CRISPR-Cas systems. Seminal experimental work demonstrated that CRISPR loci, together with Cas proteins, function as an adaptive immune defense system in bacteria and archaea by integrating fragments of bacteriophage DNA into spacer sequences to provide sequence-specific resistance against viral infection.

1:13:35Alex Marsonsupportedhigh

Jennifer Doudna and Emmanuelle Charpentier were awarded the Nobel Prize for discovering that CRISPR can be repurposed for targeted DNA cutting.

"what was recognized, and this became the basis for a Nobel Prize with Jennifer Doudna and Emmanuelle Charpentier—many people around the world have contributed to this field—what was realized was that this could be repurposed as a tool. If we take it out of bacteria, we could actually exploit this CRISPR system that had evolved to protect bacteria." (said at 1:13:35)

Jennifer Doudna and Emmanuelle Charpentier were awarded the 2020 Nobel Prize in Chemistry for developing the CRISPR/Cas9 genome editing technology. Their breakthrough showed that the CRISPR-Cas system, originally an adaptive immune defense evolved in bacteria to protect against mobile genetic elements and viruses, could be repurposed as a programmable, targeted tool for precise DNA cutting and editing.

1:15:10Alex Marsonsupportedhigh

In the CRISPR-Cas9 system, target DNA sequence specificity is determined by complementary base pairing with a guide RNA molecule.

"So, CRISPR, sometimes called Cas9, which is a particular type of CRISPR system, is a combination of a protein, which is a scissor, and then an RNA that sticks to it. And the RNA is what actually programs where that scissor will cut. Okay, so this—and what's so special about that is that we actually know with near-perfect precision the rules of how an RNA will recognize any DNA sequence. There's a complementarity where you can match up and know exactly which RNA you want to design." (said at 1:15:10)

The speaker's explanation accurately describes the fundamental mechanism of the CRISPR-Cas9 system: the Cas9 endonuclease is directed to introduce double-stranded breaks at specific DNA target sites via complementary Watson-Crick base pairing with an engineered guide RNA (or dual tracrRNA:crRNA).

1:18:45Alex Marsonsupportedhigh

David Liu at Harvard developed CRISPR base editors that change nucleotides at targeted sites without generating double-stranded DNA breaks by using a deaminase domain.

"David Liu at Harvard has created these things called CRISPR base editors that don't introduce a double-stranded break, but actually change nucleotides in a more predictable way at that site by recruiting a deaminase domain, something that will change DNA nucleotides when it's recruited to a particular place. And you use CRISPR just to recruit that enzyme that makes that mutation at a targeted place." (said at 1:18:45)

David Liu's laboratory at Harvard University developed CRISPR base editing technologies, including Cytosine Base Editors (CBEs) and Adenine Base Editors (ABEs). These systems fuse a catalytically impaired Cas9 domain (such as dCas9 or Cas9 nickase) with a cytidine or adenosine deaminase enzyme. Guided by RNA to a targeted genomic site, the deaminase domain chemically alters nucleobases directly (e.g., converting C to U or A to I) without generating double-stranded DNA breaks or requiring donor DNA templates.

1:19:35Alex Marsonsupportedhigh

CRISPR-based epigenetic editing can turn genes on or off without cutting the underlying DNA sequence.

"And now we and others are using CRISPR-based epigenetic editing. It's called epi-editing, where we don't make any cut in the genome, but we just turn on or off. And it's in a large part to think about mitigating some of these risks that might come with the scissor function." (said at 1:19:35)

CRISPR-based epigenome editing (often utilizing catalytically dead Cas proteins, such as dCas9, fused to transcriptional repressors, activators, or chromatin/DNA-modifying enzymes) enables locus-specific activation or repression of gene expression without introducing DNA double-strand breaks or altering the underlying nucleotide sequence.

1:25:48Alex Marsonsupportedhigh

Electroporation delivers genetic materials or protein-RNA complexes into cells by passing an electrical current that creates transient pores in the cell membrane.

"We put these cells into a device that gives a small electrical current to the T cells. Electroporation... You inject DNA. It's floating around in the local tissue. You pass some square-wave current... And the assumption is that it creates little transient pores in the cell membrane. And so it gets in" (said at 1:25:48)

Electroporation (also termed electropermeabilization or electrotransfection) is a well-established biophysical technique in which short electric pulses or currents are applied to cells to induce a transient increase in cell membrane permeability, primarily through the formation of transient aqueous/hydrophilic pores, allowing nucleic acids (such as DNA/RNA) and other macromolecules to enter.

1:03:25Alex Marsonsupportedhigh

Certain types of cancers, such as childhood leukemias, peak in incidence during childhood rather than in later stages of life.

"So I think there's a few cancers that peak in childhood and there's risk as the body's developing of certain childhood cancers and there's childhood leukemias, for example, like when we talk about Emily Whitehead." (said at 1:03:25)

Epidemiological data and comprehensive reviews firmly establish that acute lymphoblastic leukemia (ALL), the most common childhood cancer, has an early childhood peak in incidence (characteristically occurring between 1 and 5 years of age) rather than peaking in older adulthood.

1:27:25Alex Marsonsupportedhigh

CRISPR-mediated genome editing can insert large synthetic DNA sequences spanning hundreds to thousands of nucleotides into targeted genomic sites in primary human T cells.

"And we've pushed this boundary of being able to say, "Let's pick a site, make a cut, and introduce hundreds or up to thousands of different nucleotides to be able to really write a piece of DNA code that doesn't even have to exist in nature, but then we have the precision using CRISPR to put it into a particular place in the DNA."" (said at 1:27:25)

The speaker's claim is directly supported by published research demonstrating non-viral CRISPR-Cas9 genome targeting in primary human T cells. Roth et al. demonstrated that CRISPR-Cas9 ribonucleoproteins combined with non-viral double-stranded DNA templates can mediate homology-directed repair to knock in large synthetic DNA sequences (>1 kilobase / hundreds to thousands of base pairs) into specific genomic target loci in primary human T cells with high efficiency and preserved viability.

1:36:50Alex Marsonsupportedhigh

Over one billion people worldwide have been injected with lipid nanoparticles (LNPs), which are used to deliver mRNA vaccines.

"And the abbreviation we use is LNPs, but a billion people around the world have now been injected with LNPs. LNPs are the technology that delivered mRNA vaccines." (said at 1:36:50)

Published reviews and global surveillance data confirm that lipid nanoparticles (LNPs) are the drug delivery technology used for mRNA COVID-19 vaccines (such as BNT162b2 and mRNA-1273), and that billions of doses have been administered globally to over a billion individuals.

1:37:10Alex Marsonsupportedhigh

When injected into the body, lipid nanoparticles naturally tend to travel to the liver.

"If you inject them into the body, lipid nanoparticles naturally tend to go to the liver." (said at 1:37:10)

When standard lipid nanoparticles (LNPs) are systemically injected into the body, their default biodistribution naturally concentrates predominantly in the liver (hepatic tropism). In circulation, LNPs adsorb plasma proteins—principally apolipoprotein E (ApoE)—forming a biomolecular corona that mediates receptor-mediated cellular uptake by hepatocytes and hepatic clearance through fenestrated liver sinusoids. This natural liver tropism is well-established and formed the basis for the first clinically approved siRNA LNP therapy (patisiran/Onpattro). Delivering LNPs to extrahepatic tissues typically requires specialized formulation modifications (such as selective organ-targeting [SORT] lipids or active targeting ligands) to bypass this inherent hepatic accumulation.

1:38:30Alex Marsonsupportedvery low

Researchers at a University of Pennsylvania spinout developed targeted lipid nanoparticles that bind T cells in the bloodstream to deliver mRNA encoding CARs and generate CAR T cells in vivo.

"Actually, there's a company out of the University of Pennsylvania that developed recently a technology to make lipid nanoparticles that could be injected into the bloodstream. Think of them as these little fat bubbles, exactly as you said. But in them they included a protein that would recognize something on the surface of T cells so that as these lipid bubbles were going through the blood, they would stick preferentially to T cells and deliver mRNA to T cells. And you could actually put an mRNA into T cells that would temporarily make a gene that would encode a CAR, these artificial receptors against cancer." (said at 1:38:30)

Preclinical research led by investigators at the University of Pennsylvania (who co-founded the spinout Capstan Therapeutics) demonstrated that injecting CD5-targeted lipid nanoparticles (tLNPs) carrying modified mRNA into the bloodstream successfully transfects T cells in vivo to generate functional, transient chimeric antigen receptor (CAR) T cells. The initial landmark study demonstrated this approach in a mouse model of cardiac fibrosis, generating transient CAR T cells that reduced fibrosis and restored cardiac function. Because evidence for this specific platform remains in the preclinical/animal stage, GRADE certainty is very low.

1:45:40Alex Marsonsupportedmoderate

During the 1793 yellow fever epidemic in Philadelphia, Jeffersonian Democrats favored extreme bloodletting techniques while Federalists favored baths and gentler treatments.

"In 1793, there was a yellow fever epidemic in Philadelphia. And actually the early parties that were forming, the Federalists and the Democrats, actually took wildly dissenting views of how to deal with an epidemic. They had different views of what caused it, whether it was outside contagion or sanitation. And the Democrats at that time, the Jeffersonian Democrats, were in favor of really extreme bloodletting techniques. And the Hamiltonians, the Federalists, had a totally different set of techniques of baths and more gentle treatments." (said at 1:45:40)

Historical scholarship confirms that during the 1793 Philadelphia yellow fever epidemic, medical theories and treatments split sharply along emerging partisan lines. Dr. Benjamin Rush and his Democratic-Republican allies argued that yellow fever was not contagious from abroad but arose locally from unsanitary conditions/miasma, treating it aggressively with 'depletion therapy' (massive bloodletting and calomel purges). In contrast, Federalists (including Alexander Hamilton and physician allies) supported the theory that the disease was an imported contagion requiring quarantines and favored milder, supportive therapies such as cold baths, Peruvian bark (quinine), and wine.

1:59:00Alex Marsonsupportedhigh

Naturally occurring mutations in the CCR5 gene confer resistance to HIV infection.

"And the modifications that they decided to try to make were to delete a gene that, if it's deleted, can confer resistance to HIV. This is a gene called CCR5. There's people who naturally have a certain mutation in this at some frequency, and mutations in this gene confer resistance to HIV if they're naturally occurring." (said at 1:59:00)

The speaker accurately describes the well-established biological finding that naturally occurring loss-of-function mutations in the CCR5 gene (most notably the 32-base-pair deletion known as CCR5Δ32) confer resistance to HIV-1 infection. Individuals who are homozygous for this null mutation lack functional CCR5 coreceptors on the cell surface, preventing entry of CCR5-tropic HIV strains. This natural variation occurs at notable frequencies (particularly in European populations) and has formed the basis for gene editing approaches and stem cell transplant-based HIV cures.

1:59:35Alex Marsonsupportedmoderate

Sperm washing procedures reduce the risk of HIV transmission from an HIV-positive father to an embryo to near zero.

"First of all, there's state-of-the-art methods to reduce the risk of HIV through sperm washing and things that can be done that would, from my understanding, essentially reduce the risk to near zero of transmission from a father to an embryo." (said at 1:59:35)

A systematic review and meta-analysis of 40 observational studies evaluating sperm washing in HIV-discordant couples found zero HIV seroconversions among 3,994 uninfected female partners across 11,585 cycles of assisted reproduction (IUI, IVF, or ICSI), and no vertical transmission to infants. While randomized controlled trials have not been conducted due to ethical constraints, the large body of observational evidence consistently demonstrates that sperm washing reduces HIV transmission risk to essentially zero.

1:52:50Alex Marsonsupportedhigh

Bispecific T-cell engagers (BiTEs) are dual-binding antibodies designed to simultaneously bind a target on a cancer cell and a target on a T cell, directing endogenous T cells to kill the cancer cell without requiring genetic modification of the T cells.

"The BiTE is a proprietary term, but basically these are two-headed antibodies. One side will recognize a cancer cell and the other side will recognize a T cell and essentially bring these things together so that you get the T cell action locally to the cancer cell without having to do any genetic modification to the T cell. You actually just take advantage of T cells that are already in the body." (said at 1:52:50)

The speaker accurately describes the mechanism of action of bispecific T-cell engagers (BiTEs / T-cell engagers). BiTEs are engineered bispecific antibody constructs that simultaneously bind a specific tumor-associated antigen on target cancer cells and the CD3 receptor complex on endogenous T cells. This dual engagement physically bridges the two cells, triggering an immunological synapse and T-cell-mediated cytotoxicity without requiring ex vivo genetic engineering of the patient's T cells (in contrast to CAR T-cell therapy).

2:02:20Alex Marsonsupportedhigh

Somatic genetic edits modify DNA in individual cells such that genetic consequences are passed on to daughter cells within the individual, but are not passed on to the next generation of humans because sperm and egg cells are not edited.

"These are what we call somatic edits. These are making edits to the DNA in individual cells, where those genetic consequences will be passed on to the daughter cells, but not to the next generation of human, because we're not making genetic edits in sperm or in eggs." (said at 2:02:20)

The speaker accurately defines somatic genome editing versus germline genome editing. Somatic edits alter the DNA of non-reproductive cells (somatic cells), where the modified genome is transmitted to daughter cells within the individual via mitosis, but is not heritable across generations because gametes (sperm and eggs) and embryos are not modified.

2:03:30Andrew Huberman (host)supportedhigh

Joe Tsien at Princeton published research introducing a genetic modification to NMDA receptors to enhance learning and memory in mice.

"many years ago there was a paper—it had some issues with replication down the line, but where I think it was Joe Tsien at Princeton introduced maybe a mutant or an extra—I forget now, it's been a while. Case in point, I clearly don't have this receptor, the NMDA receptor, which is involved in plasticity in a subregion of the hippocampus. The idea was they were trying to make super smart mice." (said at 2:03:30)

Joe Tsien's laboratory at Princeton University published a landmark 1999 study in Nature (Tang et al.) demonstrating that genetic overexpression of the NMDA receptor subunit NR2B in transgenic mice ('Doogie mice') enhanced synaptic plasticity (long-term potentiation) and led to superior performance in various learning and memory tasks.

  • supports: Genetic enhancement of learning and memory in mice. (Nature 1999) · cited 1871x in the literature
    "Here we show that overexpression of NMDA receptor 2B (NR2B) in the forebrains of transgenic mice leads to enhanced activation of NMDA receptors, facilitating synaptic potentiation in response to stimulation at 10-100 Hz. These mice exhibit superior ability in learning and memory in various behavioural tasks, showing that NR2B is critical in gating the age-dependent threshold for plasticity and memory formation." (abstract, results, passage verified)
    pubmedfull study (doi)
2:03:45Andrew Huberman (host)supportedhigh

NMDA receptors are involved in synaptic plasticity in subregions of the hippocampus.

"the NMDA receptor, which is involved in plasticity in a subregion of the hippocampus." (said at 2:03:45)

Extensive neurobiological literature confirms that NMDA receptors play a foundational role in mediating synaptic plasticity (such as long-term potentiation and short-term potentiation) in subregions of the hippocampus, notably the CA1 subfield and the dentate gyrus.

2:11:40Alex Marsonsupportedmoderate

CAR-T cells engineered to eliminate B cells, which are used to treat B-cell leukemias, are showing strong responses in early clinical trials for systemic lupus erythematosus and other autoimmune diseases.

"the same CAR-T cells that are being used to get rid of B cell leukemias are also getting rid of B cells which are contributing to autoimmune disease. So, without making any change, people are already starting to see incredible responses in the early trials for lupus and other for diseases with T cells engineered to eliminate B cells." (said at 2:11:40)

Early-phase clinical trials and series have demonstrated robust clinical responses and drug-free remissions using anti-CD19 CAR-T cell therapies (the same construct class used for B-cell malignancies) in patients with severe, treatment-refractory systemic lupus erythematosus (SLE) and other B-cell-mediated autoimmune conditions (such as systemic sclerosis and idiopathic inflammatory myopathies). In early studies and basket trials, deep B-cell depletion led to complete disease remission according to standard criteria (e.g., DORIS for SLE) in the vast majority of treated patients, with reconstitution of naive non-autoreactive B cells.

2:16:05Alex Marsonsupportedhigh

Single-cell RNA sequencing combined with CRISPR perturbation allows simultaneous measurement of the delivered CRISPR guide and the full transcriptome state of individual primary human immune cells.

"Now, what we can do is we can for each genetic modification, we can do a complete measurement of the state of each individual cell. We We this is a technology called single-cell RNA sequencing. So, we measure now simultaneously all of the the RNA that's in that cell telling us giving us a snapshot of what that cell is now able to do. And we can also simultaneously measure which CRISPR was put into that cell." (said at 2:16:05)

The speaker accurately describes single-cell CRISPR screening technologies (commonly known as Perturb-seq or CROP-seq). These methods combine pooled CRISPR perturbations with single-cell RNA sequencing to simultaneously capture the identity of the specific guide RNA/perturbation introduced into each individual cell alongside its full single-cell transcriptomic readout, enabling functional genomic profiling across cellular states, including immune cells.

2:18:53Andrew Huberman (host)supportedhigh

Shinya Yamanaka demonstrated that introducing specific transcription factors (Yamanaka factors) into somatic cells such as fibroblasts can revert them into induced pluripotent stem cells.

"a colleague of yours um Yamanaka won a Nobel Prize for essentially showing that you can take a skin cell, put it in a dish, give it Yamanaka factors as it were for in some cases only three transcription factors and essentially revert that cell to a stem cell and then give it some other transcription factors and turn it into I don't know a neuron or a pancreatic cell." (said at 2:18:53)

Shinya Yamanaka and colleagues famously demonstrated in landmark 2006 (mouse) and 2007 (human) studies that somatic cells, specifically adult and embryonic fibroblasts, can be reprogrammed into induced pluripotent stem cells (iPSCs) using a specific combination of transcription factors (Oct3/4, Sox2, Klf4, and c-Myc; commonly known as the Yamanaka factors). Yamanaka shared the 2012 Nobel Prize in Physiology or Medicine for this discovery.

2:20:10Alex Marsonsupportedmoderate

Induced pluripotent stem cells (iPSCs) can be differentiated into functional T cells.

"one of the interesting areas is actually imagining how these iPS cells could be made into T cells, which would essentially create a limitless supply of T cells" (said at 2:20:10)

The speaker's claim is supported. Extensive translational and preclinical research demonstrates that human induced pluripotent stem cells (hiPSCs) can be differentiated into functional T-cell lineages (including CD8+ cytotoxic T cells, CD4+ helper T cells, and CAR-T cells). Because hiPSCs have indefinite self-renewal capacity, they offer a scalable, renewable platform for off-the-shelf cell therapy.

2:20:24Alex Marsonsupportedhigh

Shinya Yamanaka and colleagues have established an induced pluripotent stem cell (iPSC) bank of HLA-compatible cell lines designed to support allogeneic cell transplantation across diverse human populations.

"one of the things that he's been involved with is actually building sort of a bank of iPS cells that would be compatible immune compatible with broad sets of different people so that it could essentially be used as a transplant bank" (said at 2:20:24)

Shinya Yamanaka and his team at the Center for iPS Cell Research and Application (CiRA) established a clinical-grade induced pluripotent stem cell (iPSC) stock/haplobank using cells from donors homozygous for major human leukocyte antigen (HLA) haplotypes. This project was specifically designed to provide immune-matched, allogeneic cell lines for broad segments of the population to facilitate clinical transplantation therapies.

4 No source found (not proven false)
0:53:59Alex Marsonunverifiedvery low

Jimmy Carter was treated with immune checkpoint inhibitors for metastatic melanoma that had spread to his brain, achieving remission.

"One of the big success cases was Jimmy Carter, who had a melanoma, which is a skin cell, aggressive skin cancer that had already gone to his brain, which was thought of as a death sentence. And he got treated with checkpoint inhibitors and basically was cured." (said at 0:53:59)

Former US President Jimmy Carter was widely publicized in 2015 for receiving the immune checkpoint inhibitor pembrolizumab (along with stereotactic radiation and liver surgery) for metastatic melanoma with brain metastases, achieving a durable complete response (remission). However, per the verification protocol for named individual patient cases, no formal peer-reviewed case report published in the biomedical literature indexed in PubMed/Europe PMC was identified documenting his specific clinical records. As a single public patient case / uncontrolled anecdote without an indexed scientific case report, the certainty is very_low.

1:28:28Alex Marsonunverifiedlow

ArsenalBio is in clinical trials testing CRISPR-engineered T-cell therapies for solid tumors, including prostate cancer.

"We started a company when that technology worked, a company called ArsenalBio that's now in clinical trials. It's actually in its third clinical trial right now for solid tumors. It's in a clinical trial for prostate cancer that's about to start enrolling patients." (said at 1:28:28)

ArsenalBio is a clinical-stage biotechnology company developing non-viral CRISPR-engineered programmable T-cell (CAR-T) therapies for solid tumors, with pipeline candidates including AB-1015 (for ovarian cancer) and AB-2100 (targeting PSMA-positive tumors such as prostate and renal cancers). However, no peer-reviewed journal articles detailing the clinical trial results or enrollment status for these specific ArsenalBio trials were identified in PubMed records at the time of verification. This absence of indexed clinical trial literature does not prove the claim false, as early-phase trials are typically documented in clinical trial registries prior to peer-reviewed publication.

1:32:00Alex Marsonunverifiedvery low

The Gladstone-UCSF Institute of Genomic Immunology is conducting a CRISPR clinical trial for the treatment of multiple myeloma.

"We're actually starting academically in an institute that I run, the Gladstone-UCSF Institute of Genomic Immunology, we're starting a philanthropically funded CRISPR trial for multiple myeloma where we're using a different genetic program." (said at 1:32:00)

No published clinical trial protocol or published trial results describing a philanthropically funded academic CRISPR trial for multiple myeloma led by the Gladstone-UCSF Institute of Genomic Immunology were identified in the searched biomedical databases. While Dr. Alex Marson directs the Gladstone-UCSF Institute of Genomic Immunology and conducts research into CRISPR gene editing in human T cells, specific institutional trial initiatives or newly launching clinical studies often lack formal peer-reviewed publications during their early operational stages. This lack of published peer-reviewed records does not mean the trial does not exist, but renders the specific claim unverified in the medical literature.

2:16:20Alex Marsonunverifiedlow

Alex Marson's laboratory released a functional genomics dataset mapping the single-cell RNA sequencing profiles of 22 million primary human immune cells with CRISPR gene knockouts.

"We just released 22 million cells where each one has a different CRISPR gene inactivated and we get a map of this" (said at 2:16:20)

No published or indexed peer-reviewed record matching a specific dataset of 22 million primary human immune cells with CRISPR gene knockouts from the Marson laboratory could be verified in the search. While the Marson lab regularly publishes pooled CRISPR perturbation studies and single-cell RNA sequencing datasets in primary human T cells (for example, perturbing 84 transcription factor genes in primary CD4+ T cells; PMID: 39395408), the specific spoken scale of 22 million perturbed single cells may represent a recent pre-print, unpublished repository release, or consortium data release not indexed in standard biomedical literature databases.

Unverified means no publication matching the claim was located; it does not prove the claim false. Spotted an error? See the corrections policy - disputes from the people quoted are prioritized.